

#5747
Store at -20°C

EGF Receptor (E746-A750del Specific) (D6B6) XP® Rabbit mAb (Biotinylated)



Cell Signaling
TECHNOLOGY®

Orders: 877-616-CELL (2355)
orders@cellsignal.com

Support: 877-678-TECH (8324)

Web: info@cellsignal.com
cellsignal.com

3 Trask Lane | Danvers | Massachusetts | 01923 | USA

For Research Use Only. Not for Use in Diagnostic Procedures.

Applications: WB	Reactivity: H	Sensitivity: Endogenous	MW (kDa): 175	Source/Isotype: Rabbit IgG	UniProt ID: #P00533	Entrez-Gene Id: 1956
---------------------	------------------	----------------------------	------------------	-------------------------------	------------------------	-------------------------

Product Usage Information	Application Western Blotting	Dilution 1:1000
Storage	Supplied in 136 mM NaCl, 2.6 mM KCl, 12 mM sodium phosphate (pH 7.4) dibasic, 2 mg/ml BSA, and 50% glycerol. Store at -20°C. Do not aliquot the antibodies.	
Specificity / Sensitivity	EGF Receptor (E746-A750del Specific) (D6B6) XP® Rabbit mAb (Biotinylated) detects endogenous levels of EGFR E746-A750del mutant protein.	
Source / Purification	Monoclonal antibody is produced by immunizing animals with a synthetic peptide corresponding to E746-A750del mutant sequence of human EGFR.	
Product Description	This Cell Signaling Technology antibody is conjugated to biotin under optimal conditions. The biotinylated antibody is expected to exhibit the same species cross-reactivity as the unconjugated EGF Receptor (E746-A750del Specific) (D6B6) XP® Rabbit mAb #2085.	

MW (kDa)	175
----------	-----

Background	The epidermal growth factor (EGF) receptor is a 170 kDa transmembrane tyrosine kinase that belongs to the HER/ErbB protein family. Research studies have shown that somatic mutations in the tyrosine kinase domain of EGF receptor (EGFR) are present in a subset of lung adenocarcinomas that respond to EGFR inhibitors, such as gefitinib and erlotinib (1-3). Two types of mutations account for approximately 90% of mutated cases: a specific point mutation, L858R, that occurs in exon 21 and short in-frame deletions in exon 19 (4,5). The most frequent exon 19 deletion is E746-A750, accounting for 90% of lesions at this site, although some rare variants occur.
-------------------	---

Background References	<ol style="list-style-type: none"> Lynch, T.J. et al. (2004) <i>N Engl J Med</i> 350, 2129-39. Pao, W. et al. (2004) <i>Proc Natl Acad Sci USA</i> 101, 13306-11. Haber, D.A. et al. (2005) <i>Cold Spring Harb Symp Quant Biol</i> 70, 419-26. Kosaka, T. et al. (2004) <i>Cancer Res</i> 64, 8919-23. Riely, G.J. et al. (2006) <i>Clin Cancer Res</i> 12, 7232-41.
------------------------------	--

Species Reactivity	Species reactivity is determined by testing in at least one approved application (e.g., western blot).
Western Blot Buffer	IMPORTANT: For western blots, incubate membrane with diluted primary antibody in 5% w/v BSA, 1X TBS, 0.1% Tween® 20 at 4°C with gentle shaking, overnight.
Applications Key	WB: Western Blotting
Cross-Reactivity Key	H: human M: mouse R: rat Hm: hamster Mk: monkey Vir: virus Mi: mink C: chicken Dm: D. melanogaster X: Xenopus Z: zebrafish B: bovine Dg: dog Pg: pig Sc: S. cerevisiae Ce: C. elegans Hr: horse GP: Guinea Pig Rab: rabbit All: all species expected
Trademarks and Patents	Cell Signaling Technology is a trademark of Cell Signaling Technology, Inc. XP is a registered trademark of Cell Signaling Technology, Inc. All other trademarks are the property of their respective owners. Visit cellsignal.com/trademarks for more information.
Limited Uses	

Except as otherwise expressly agreed in a writing signed by a legally authorized representative of CST, the following terms apply to Products provided by CST, its affiliates or its distributors. Any Customer's terms and conditions that are in addition to, or different from, those contained herein, unless separately accepted in writing by a legally authorized representative of CST, are rejected and are of no force or effect.

Products are labeled with For Research Use Only or a similar labeling statement and have not been approved, cleared, or licensed by the FDA or other regulatory foreign or domestic entity, for any purpose. Customer shall not use any Product for any diagnostic or therapeutic purpose, or otherwise in any manner that conflicts with its labeling statement. Products sold or licensed by CST are provided for Customer as the end-user and solely for research and development uses. Any use of Product for diagnostic, prophylactic or therapeutic purposes, or any purchase of Product for resale (alone or as a component) or other commercial purpose, requires a separate license from CST. Customer shall (a) not sell, license, loan, donate or otherwise transfer or make available any Product to any third party, whether alone or in combination with other materials, or use the Products to manufacture any commercial products, (b) not copy, modify, reverse engineer, decompile, disassemble or otherwise attempt to discover the underlying structure or technology of the Products, or use the Products for the purpose of developing any products or services that would compete with CST products or services, (c) not alter or remove from the Products any trademarks, trade names, logos, patent or copyright notices or markings, (d) use the Products solely in accordance with CST Product Terms of Sale and any applicable documentation, and (e) comply with any license, terms of service or similar agreement with respect to any third party products or services used by Customer in connection with the Products.